Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease

NCT01903811 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT01903811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01903811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2013
Completion date
March 7, 2019
Enrollment
143 (actual)
Sites
485

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent plasma cell myeloma, refractory plasma cell myeloma